

## Development of peptide vaccine against the pancreatic or lung cancers with KRAS mutation

NA Vaccine Institute



ONCOLOGY	Candidate
Product Type	Peptide vaccine (Peptide + Adjuvant)
Indication	Lung cancer or pancreatic cancer with KRAS G12 mutations
Target	Cancer cells with KRAS G12 mutations
MoA(Mechanism of Action)	Cancer cells killing by KRAS G12 mutations-specific T cell responses
Competitiveness	Currently, Lumakras(Amgen) is approved in the United States with a treatment that can treat cancer with KRAS mutations. However, only G12C KRAS mutations in non-small cell lung cancer can be targeted, and there is a disadvantage that the duration of drug response is short. It is urgent to develop treatments that can treat lung cancer, pancreatic cancer, biliary tract cancer, and digestive cancer with KRAS mutation, and that can cover various major KRAS mutations.
Development Stage	Candidate
Route of Administration	Intramuscular / inhaled route